How you eat may be just as important as how much you eat, if mice studies are any clue.

Cancer researchers have long studied the role of diet on breast cancer risk, but results to date have been mixed. New findings published in Cancer Prevention Research, a journal of the American Association for Cancer Research, suggest the method by which calories are restricted may be more important for cancer protection than the actual overall degree of calorie restriction.

“Understanding how calorie restriction provides protection against the development of mammary tumors should help us identify pathways that could be targeted for chemoprevention studies,” said Margot P. Cleary, Ph.D., professor at The Hormel Institute, University of Minnesota. “Further identification of serum factors that are involved in tumor development would possibly provide a way to identify at risk individuals and target interventions to these people.”

Previous studies have shown that intermittent calorie restriction provided greater protection from mammary tumor development than did the same overall degree of restriction, which was implemented in a chronic fashion. The researchers compared changes of a growth factor (IGF-1) in relationship to these two calorie restriction methods — chronic and intermittent — and tumor development beginning in 10-week old female mice at risk to develop mammary tumors. Their hope was to explain why intermittent restriction is more effective.

The overall degree of restriction was 25 percent reduction compared to control mice. Mammary tumor incidence was 71 percent in the control mice who ate the amount of food they wanted, 35 percent among those who were chronically restricted and only nine percent in those who intermittently restricted calories.

The researchers were initially surprised by these findings for several reasons. First, the prevailing wisdom is that the degree of protection from calorie restriction is proportional to the degree of mammary tumor prevention. Second, they originally thought that intermittent calorie restriction might enhance tumor growth due to growth factors being secreted in response to re-feeding, Cleary said.

In an accompanying editorial also published in Cancer Prevention Research, Michael Pollak, M.D., stated that some major challenges of pharmacologic approaches to cancer prevention and/or treatment include defining the underlying causes and determining the relevance of these caloric restriction methods. Pollak is professor of oncology at McGill University and director of the Cancer Prevention Center at the Jewish General Hospital, both in Montreal.

This study “contributes to accumulating evidence that caloric restriction acts by altering hormone levels rather than by directly starving cancers of energy. In particular, lower levels of insulin are associated with reduced food intake, and this may be protective,” said Pollak, who is also an editorial board member for Cancer Prevention Research.

In the editorial Pollak wrote: “there is reason for concern that the ‘obesity epidemic’ may lead to an increased prevalence of a hormonal profile associated with elevated cancer risk and/or an adverse cancer prognosis. Therefore, in addition to its well-known general health benefits, maintaining an ideal body weight is also important in the specific contexts of cancer prevention and improving the prognosis of cancer patients.”

Based on varied findings from clinical trials, Pollak suggested that lifestyle and pharmacologic methods to reduce IGF-1 and insulin deserve ongoing investigations. Cleary agreed, stating that these results may provide interest to more aggressively pursue cancer prevention studies related to calorie restriction.

“Humans frequently regain lost weight discouraging the application of calorie restriction protocols for disease prevention,” she said. “We hope these studies will identify biomarkers and/or pathways that could be used in human studies to determine agents that would mimic calorie restriction.”

Additional Resources:
Note: a PDF of this study and an editorial are available on request.

The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, AACR is the world’s oldest and largest professional organization dedicated to advancing cancer research. The membership includes more than 28,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and nearly 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants. The AACR Annual Meeting attracts more than 17,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. The AACR publishes six major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists. CR provides a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship and advocacy.

Source: American Association for Cancer Research (AACR)